Valuation: Silence Therapeutics plc

Market Cap 509M 674M 593M 561M 955M 64.73B 961M 6.72B 2.59B 33.03B 2.53B 2.48B 106B P/E 2026 *
-21.1x
P/E 2027 * -16.9x
Enterprise Value 376M 498M 438M 414M 705M 47.79B 709M 4.96B 1.91B 24.39B 1.87B 1.83B 78.37B EV / Sales 2026 *
1,165x
EV / Sales 2027 * 446x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -
3 months+81.82%
6 months+100.00%
Current year+100.00%
1 week 4
Extreme 4
4
1 month 4
Extreme 4
4
Current year 1.06
Extreme 1.06
5.99
1 year 1.06
Extreme 1.06
5.99
3 years 0.5
Extreme 0.4986
14.75
5 years 0.5
Extreme 0.4986
46.5
10 years 0.5
Extreme 0.4986
46.5
Manager TitleAgeSince
Chief Executive Officer 72 2025-11-30
Director of Finance/CFO 54 2022-01-31
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 63 2018-06-20
Chairman 72 2003-12-31
Director/Board Member 65 2025-05-04
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 674M
+2.64%+6.45%+11.87%+38.40% 49.06B
+0.22%+0.40%+50.91%+37.06% 44.6B
-1.58%+4.66%+359.34%+614.38% 43.24B
+1.70%+0.36%+12.56%+99.27% 41.73B
+0.51%-1.71%+5.18%+46.87% 29.93B
-0.48%-1.32%+23.98%+150.01% 17.19B
+0.08%+9.03%+8.41% - 15.35B
+1.76%+0.85%+29.13%+48.42% 15.54B
+1.97%-3.17% - - 15.11B
Average +0.68%+1.85%+62.67%+147.77% 30.19B
Weighted average by Cap. +0.76%+2.26%+78.18%+161.54%

Financials

2026 *2027 *
Net sales 322K 427K 376K 355K 606K 41.03M 609K 4.26M 1.64M 20.94M 1.6M 1.57M 67.28M 751K 995K 875K 827K 1.41M 95.51M 1.42M 9.91M 3.83M 48.73M 3.74M 3.65M 157M
Net income -42.14M -55.86M -49.13M -46.46M -79.13M -5.36B -79.59M -556M -215M -2.74B -210M -205M -8.79B -71.01M -94.14M -82.79M -78.29M -133M -9.04B -134M -937M -362M -4.61B -353M -346M -14.82B
Net Debt -133M -176M -155M -147M -250M -16.94B -251M -1.76B -679M -8.64B -662M -648M -27.77B -174M -231M -203M -192M -327M -22.15B -329M -2.3B -887M -11.3B -866M -847M -36.32B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.20USD
Average target price
33.00USD
Spread / Average Target
+194.64%

Quarterly revenue - Rate of surprise